Methods of protecting an organ using tetrahydrocurcumin and phosphatidylcholine

Abstract

Pharmaceutical formulations of tetrahydrocurcumin and liposomes are described herein. The liposomes may comprise at least a first lipid, wherein the first lipid is a phospholipid or polyenylphosphatidylocholine are also disclosed.

What is claimed is: 
     
         1 . A method of treating, inhibiting, or ameliorating a disorder in a subject comprising:
 administering a pharmaceutical formulation to the subject, the pharmaceutical formulation comprising a non-deuterated form of tetrahydrocurcumin or a deuterated form of tetrahydrocurcumin and a pharmaceutical vehicle.   
     
     
         2 . The method of  claim 1 , wherein the disorder is selected from a group consisting of consisting of fatty liver disease, alcoholic liver disease, kidney disease, diabetic kidney disease, polycystic kidney disease, hypertension, hypertension with left ventricular hypertrophy, heart failure, diabetes and diabetes with hyperlipidemia. 
     
     
         3 . The method of  claim 1 , wherein the disorder is chronic kidney disease. 
     
     
         4 . The method of  claim 1 , wherein the subject has elevated levels of Galectin-3, fibrotic markers, markers of oxidative stress, and/or markers of inflammation in the blood and/or urine, or , wherein the subject is taking analgesics, or wherein the subject is under treatment with one or more anti-malarial drugs. 
     
     
         5 . The method of  claim 1 , wherein the pharmaceutical formulation is administered by oral administration or intravenous administration. 
     
     
         6 . A method of protecting an organ, comprising:
 identifying a subject in need of protection of an organ; and   administering a pharmaceutical formulation to a subject in need thereof, the pharmaceutical formulation comprising a non-deuterated form of tetrahydrocurcumin or a deuterated form of tetrahydrocurcumin and a pharmaceutical vehicle.   
     
     
         7 . The method of  claim 6 , wherein the organ is selected from a group consisting of kidney, liver and heart. 
     
     
         8 . The method of  claim 6 , wherein the administering is performed by oral administration or intravenous administration. 
     
     
         9 . The method of  claim 6 , wherein the subject has a disorder selected from a group consisting liver disorder, fatty liver disease, alcoholic liver disease, kidney disease, chronic kidney disease, diabetic kidney disease, polycystic kidney disease, hypertension, hypertension with left ventricular hypertrophy, diabetes, diabetes with hyperlipidemia and heart failure. 
     
     
         10 . The method of  claim 5 , wherein the subject has an elevated level of Galectin-3, fibrotic markers, markers of oxidative stress and/or one or more markers of inflammation in the blood and/or urine. 
     
     
         11 . A method of treating or preventing heart failure in a subject in need, comprising:
 identifying a subject in need of treatment for or prevention of heart failure; and   administering pharmaceutical formulation to a subject in need thereof, the pharmaceutical formulation comprising a non-deuterated form of tetrahydrocurcumin or a deuterated form of tetrahydrocurcumin and a pharmaceutical vehicle.   
     
     
         12 . The method of  claim 10 , wherein the subject has chronic kidney disease and/or hypertension. 
     
     
         13 . The method of  claim 10 , wherein the administering is oral administration or intravenous administration. 
     
     
         14 . A pharmaceutical formulation comprising a non-deuterated form of tetrahydrocurcumin or a deuterated form of tetrahydrocurcumin and a pharmaceutical vehicle. 
     
     
         15 . The pharmaceutical formulation of  claim 13 , further comprising a first lipid, wherein the first lipid is a phospholipid or polyenylphosphatidylcholine, and wherein the pharmaceutical formulation comprises at least 5% of the first lipid by weight and no more than 95% of the first lipid by weight. 
     
     
         16 . The pharmaceutical formulation of  claim 14 , further comprising a second lipid, and wherein the pharmaceutical formulation comprises at least 5% of the second lipid by weight and no more than 95% of the second lipid by weight. 
     
     
         17 . The pharmaceutical formulation of  claim 13 , wherein the pharmaceutical formulation further comprises an antioxidant, and wherein the pharmaceutical formulation comprises at least 5% of antioxidant by weight and no more than 95% of the antioxidant by weight, and wherein the antioxidant is selected from a group consisting of Vitamin E, Vitamin C and alpha lipoic acid. 
     
     
         18 . The pharmaceutical formulation of  claim 13 , wherein the pharmaceutical formulation further comprises curcumin, a terpenoid, cysteamine, pantethine, and/or baicalin. 
     
     
         19 . The pharmaceutical formulation of  claim 13 , wherein the vehicle is a lipophilic solvent, fatty oil, organic oil, or liposome. 
     
     
         20 . The pharmaceutical formulation of  claim 13 , wherein the pharmaceutical formulation further comprises an excipient, wherein the excipient is a sugar, lactose, sucrose, mannitol, sorbitol, cellulose preparations of maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).